Sanofi India Limited

Sanofi India Limited, established in 1956 as Hoechst Fedco Pharma Private Limited, is a leading pharmaceutical company headquartered in Mumbai, India. Over the decades, it has undergone several name changes, including Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, and Aventis Pharma Limited, before adopting its current name in May 2012. The company is a subsidiary of Hoechst GmbH, which, along with Sanofi, holds a combined 60.4% stake in Sanofi India Limited.

Sanofi India Limited operates in the pharmaceutical sector, focusing on the manufacturing and trading of drugs and pharmaceutical products. The company employs approximately 1,225 individuals and offers a diverse portfolio of products across various therapeutic areas, including diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, central nervous system disorders, allergy, pain care, digestive, and nutritional health. Its product range includes well-known brands such as Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil.

Sanofi India Limited operates a state-of-the-art manufacturing facility in Goa, India. This site is designed to meet international Good Manufacturing Practice (GMP) requirements and has received approvals from major international regulatory agencies, including the German FDA, the European Economic Area (EAEU), and the Therapeutic Goods Administration (TGA) of Australia. The Goa facility is capable of producing up to 5 billion tablets and capsules annually, serving both domestic and export markets.

As of March 2026, the key leadership team at Sanofi India Limited includes:

• Deepak Arora: Managing Director and General Manager of Pharma.

• Rachid Ayari: Chief Financial Officer and Whole-Time Director.

• Haresh Vala: Company Secretary and Compliance Officer.

• Bratin Bag: Senior Director of Ethics and Business Integrity, South Asia.

• Mahadev Gawade: Additional Whole-Time Director and Site Director - Goa.

These leaders play pivotal roles in steering the company's strategic direction and ensuring compliance with regulatory standards.

Sanofi India Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Goa has received approvals from the German FDA, EAEU, and TGA, indicating compliance with stringent international standards. This facilitates the export of its products to these regions. Additionally, Sanofi India's products are marketed under various brands, such as Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil, through independent distributors.

Sanofi India Limited has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to international GMP standards and its manufacturing facility's approvals from agencies like the German FDA, EAEU, and TGA enhance its ability to access these markets. While specific details on WHO prequalification are not provided, the company's compliance with international standards positions it favorably for entry into these regions.

Sanofi India Limited's geographic strategy demonstrates a balanced approach between domestic and international markets. The company's manufacturing capabilities in Goa, approved by major international regulatory agencies, support both domestic distribution and exports to regulated markets. This diversification mitigates concentration risk and aligns with Sanofi's global presence in over 60 countries.

Sanofi India Limited's manufacturing facility in Goa has received approvals from the German FDA, EAEU, and TGA, indicating compliance with international standards. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the facility's international approvals suggest a strong standing in regulatory compliance.

Sanofi India Limited's manufacturing facility in Goa is designed to meet international GMP requirements and has received approvals from major international regulatory agencies, including the German FDA, EAEU, and TGA. While specific details regarding WHO prequalification and EU GMP certificates are not provided, the facility's adherence to international standards positions the company favorably in global markets.

Sanofi India Limited operates under the regulatory oversight of the Central Drugs Standard Control Organization (CDSCO) in India. The company's manufacturing facility in Goa is approved by major international regulatory agencies, including the German FDA, EAEU, and TGA, indicating compliance with stringent international standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

As of March 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Sanofi India Limited. The company's manufacturing facility in Goa has received approvals from major international regulatory agencies, including the German FDA, EAEU, and TGA, indicating a strong compliance record.

Sanofi India Limited operates in a competitive pharmaceutical market, facing competition from both multinational and domestic companies. Key competitors include Aurobindo Pharma Ltd, Torrent Pharmaceuticals Ltd, Strides Pharma Science Ltd, and GlaxoSmithKline Pharmaceuticals Ltd. While specific market share comparisons are not provided, Sanofi India's diverse product portfolio and adherence to international standards position it as a significant player in the Indian pharmaceutical industry.

Sanofi India Limited's key differentiators include its extensive experience in the Indian pharmaceutical market, a diverse product portfolio across various therapeutic areas, and manufacturing facilities that adhere to international GMP standards. The Goa facility's approvals from major international regulatory agencies, such as the German FDA, EAEU, and TGA, further enhance the company's competitive advantage.

Sanofi India Limited's strategic direction focuses on delivering innovative healthcare solutions in preventive care, such as vaccines, and therapies for chronic conditions like diabetes and rare diseases. The company's adherence to international GMP standards and its manufacturing facility's approvals from agencies like the German FDA, EAEU, and TGA support its global expansion efforts. While specific details on future strategic initiatives are not publicly disclosed, the company's commitment to quality and innovation positions it well for sustained growth.

Sanofi India Limited demonstrates a strong track record in manufacturing and exporting pharmaceutical products. The company's manufacturing facility in Goa is approved by major international regulatory agencies, including the German FDA, EAEU, and TGA, indicating a high level of reliability and compliance. Specific details regarding export volume and consistency are not publicly disclosed, but the company's adherence to international standards suggests a reliable supply chain.

Importers should verify the following certifications when considering Sanofi India Limited as a supplier:

• FDA Approval: Confirm that the manufacturing facility is registered with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Ensure the facility adheres to World Health Organization Good Manufacturing Practice (GMP) standards.

• EU GMP Certification: Verify compliance with European Union GMP standards.

• ISO Certification: Check for relevant International Organization for Standardization (ISO) certifications.

These certifications can typically be verified through the respective regulatory agencies' official websites or by contacting Sanofi India Limited directly.